Mass spectrometry imaging shows promise in diagnosing brain diseases

Reviewed by Emily Henderson, B.Sc.Jan 7 2021

Medical professionals all want to be able to quickly and correctly diagnose diseases. Their future ability to do so will depend on identifying what biochemicals are present in tissue sections, where the biomolecules are, and at what concentrations.

For this purpose, mass spectrometry imaging—which can identify multiple biochemicals in a single experiment—will be useful. However, the stability of biomolecular sampling needs improvement to obtain the chemical distribution information with high spatial resolution.

In the recent study published in Analytical Chemistry, researchers from Osaka University used mass spectrometry to image the distribution of fat molecules in mouse brain tissue. They acquired data at a spatial resolution of 6.5 micrometers, enabling analysis on a cellular level.

The researchers used a very small capillary to gently extract lipid molecules from a tissue section, and a carefully designed setup for fine 3D directional control. Although biological tissue may often seem smooth to the naked eye, on an ultrasmall scale it's rather rough. The ability to account for this ultrasmall-scale roughness is central to obtaining reproducible biochemical data at high spatial resolution.

In our experiments, the probe's vibration amplitude is constant even when the sample height changes. We can also measure changes in sample height up to 20 micrometers, and it can be increased up to 180 micrometers."

Yoichi Otsuka, Study First Author, Osaka University

The researchers' first experiments were to measure irregular distributions of molecules across an uneven surface: microwells filled with various concentrations of a dye. The measured concentrations correlated with the known concentrations, and the measured surface topography was close to the actual microwell diameter. Experiments with mouse brain sections yielded a multi-dimensional data of multiple molecules such as the distribution of certain hexosylceramides—lipids that are important in aging.

"Principle component analysis helped us integrate our wide-ranging data," explains Takuya Matsumoto, senior author. "For example, we could assign the classes of lipids that are primarily present in the cortex and brainstem."

Correlating such data with disease progression will require further study and perhaps additional development of the researchers' biomolecule extraction setup. The researchers anticipate that their approach will be useful for quantitatively imaging the myriad neural networks in brain tissue. Ultimately, they hope to help medical practitioners reliably diagnose diseases such as brain cancer in a tissue section with the support of molecular information in high spatial resolution.